Response to "can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?": evaluation of CYP3A activity with microdoses of midazolam.

scientific article published on 6 February 2014

Response to "can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?": evaluation of CYP3A activity with microdoses of midazolam. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/CLPT.2014.28
P8608Fatcat IDrelease_mipmvaux6nhxzhh5faxoyfpgya
P698PubMed publication ID24503628

P50authorGerd MikusQ37382592
Walter E HaefeliQ38641417
Nicolas HohmannQ83263915
P2093author name stringB Halama
N Siller
P2860cites workEffects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteersQ33442267
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.Q48025123
Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugsQ48665583
Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing StudyQ84472792
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)490-491
P577publication date2014-02-06
P1433published inClinical Pharmacology & TherapeuticsQ1101529
P1476titleResponse to "can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?": evaluation of CYP3A activity with microdoses of midazolam
P478volume95

Reverse relations

cites work (P2860)
Q38763583CYP3A activity: towards dose adaptation to the individual.
Q35023726Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans
Q99234124Phase 0/microdosing approaches: time for mainstream application in drug development?
Q40996401Use of microdose phenotyping to individualise dosing of patients

Search more.